Cytomx Therapeutics Inc Stock Price, News & Analysis

CytomX Therapeutics (Nasdaq: CTMX) reported Q2 2025 financial results and significant clinical progress. The company announced positive interim data from Phase 1 study of CX-2051, their first-in-class EpCAM Antibody Drug Conjugate for advanced colorectal cancer, with Phase 2 study initiation planned for 1H 2026. CytomX also initiated combination dose escalation of CX-801 with KEYTRUDA® for advanced melanoma.

Financially, CytomX completed a $100 million common stock offering and ended Q2 2025 with $158.1 million in cash. Revenue was $18.7 million, down from $25.1 million year-over-year. Operating expenses decreased to $19.9 million from $33.6 million in Q2 2024. The company expects its cash runway to extend to Q2 2027.

CytomX Therapeutics (Nasdaq: CTMX), a leader in masked, conditionally activated biologic therapeutics, will release its second quarter 2025 financial results on Thursday, August 7, 2025, after U.S. markets close.

The company will host a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT. Investors can access the live webcast through CytomX's investor relations website and are advised to register at least 10 minutes before the call. A replay will be available on the company's website after the event.

CytomX Therapeutics (NASDAQ: CTMX), a company specializing in masked, conditionally activated biologics, has announced its participation in the upcoming Jefferies Global Healthcare Conference. CEO and Chairman Sean McCarthy will engage in a fireside chat on June 5, 2025, at 2:35 p.m. ET. The presentation will be accessible via live webcast on the company's website at www.cytomx.com under the Events and Presentations section. The company's management team will also be available for one-on-one meetings with registered conference attendees.

CytomX Therapeutics (NASDAQ: CTMX) has announced the dosing of the first patient with CX-801 in combination with KEYTRUDA® in an ongoing Phase 1 study for metastatic melanoma patients. CX-801 is a masked interferon alpha-2b PROBODY® cytokine designed to target tumors while reducing systemic toxicities. The combination trial follows successful clearance of three CX-801 monotherapy dose escalation cohorts. The study aims to address the high unmet need in PD-1 refractory melanoma patients. While interferon alpha-2b has proven anti-cancer activity, its use has been limited due to poor tolerability. Initial Phase 1a translational and biomarker data are expected in the second half of 2025.

CytomX Therapeutics (NASDAQ:CTMX) has announced the pricing of an underwritten public offering of 76,923,076 shares of common stock at $1.30 per share, aiming to raise approximately $100 million in gross proceeds. The offering, expected to close on May 13, 2025, features participation from notable investors including Longitude Capital, OrbiMed, Venrock Healthcare Capital Partners, Vivo Capital, and RTW Investments.

The company plans to use the proceeds for research and development, general corporate purposes, and working capital needs. Jefferies and Piper Sandler are serving as joint book-running managers for the offering, which is being conducted through an effective shelf registration statement filed with the SEC.

CytomX Therapeutics (NASDAQ: CTMX) reported Q1 2025 financial results and significant clinical progress. The company announced positive interim data from its Phase 1 study of CX-2051, an EpCAM Antibody Drug Conjugate for advanced colorectal cancer, initiating dose expansions at 7.2, 8.6, and 10 mg/kg doses. A Phase 2 study is planned for 1H 2026. Financially, CytomX ended Q1 2025 with $79.9 million in cash, reporting revenue of $50.9 million (up from $41.5M in Q1 2024) and reduced operating expenses of $28.3 million. The company achieved a $5 million milestone payment from Astellas and extended its cash runway into Q2 2026 through cost reductions. Their pipeline includes CX-801, a PROBODY Interferon alpha-2b, currently in Phase 1 trials for melanoma.

CytomX Therapeutics (NASDAQ: CTMX) reported positive interim Phase 1 data for CX-2051, their EpCAM PROBODY® ADC candidate for advanced colorectal cancer (CRC). Key findings include a 28% confirmed response rate in unselected patients across expansion doses (7.2, 8.6, and 10 mg/kg Q3W), with a notable 43% response rate at 10 mg/kg. The study showed a median progression-free survival of 5.8 months and a 94% disease control rate. Safety profile was encouraging with no dose-limiting toxicities. The trial included 25 heavily pretreated patients with a median of 4 prior therapy lines. Most adverse events were Grade 1 or 2, with diarrhea and nausea being most common. CytomX plans to initiate Phase 2 studies in 1H 2026 and is exploring potential combinations and expansion into other EpCAM-expressing tumors.

CytomX Therapeutics (NASDAQ: CTMX), a company specializing in masked, conditionally activated biologics, has scheduled its first quarter 2025 financial results announcement for Monday, May 12, 2025, before U.S. markets open. The company will host a conference call and webcast at 8:00 a.m. ET / 5:00 a.m. PT following the announcement.

Interested participants can access the live webcast through CytomX's investor relations website and are advised to register for the conference call at least 10 minutes before it begins. A replay of the webcast will be made available on the company's website after the event.

CytomX Therapeutics and Moderna have unveiled promising preclinical data for their collaborative development of an mRNA-encoded masked IL-12 molecule at the AACR Annual Meeting in Chicago.

The breakthrough combines CytomX's PROBODY® masking technology with Moderna's mRNA expertise to create a novel cancer treatment approach. The key innovation lies in developing an IL-12 therapeutic that can be selectively activated within the tumor microenvironment while minimizing systemic activity.

Key highlights:

• Successfully demonstrated proof of concept for mRNA encoded masked molecule in cancer treatment
• Achieved enhanced tolerability while maintaining anti-tumor efficacy
• Addresses previous limitations of IL-12's clinical use due to inflammatory toxicity

The research findings will be presented in Poster #3127/12 on April 28, 2025, highlighting how this innovative combination of technologies could potentially overcome traditional IL-12 therapy limitations.